Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
As a specialty provider of primary insurance services Great Lakes Insurance SE (GLISE) with its branches in the UK, Australia, Switzerland, Italy and Ireland and its newly founded subsidiary in the UK, is an integral part